Mixed cryoglobulinaemia (cryoglobulinaemic vasculitis)
Bedside summary
Small-to-medium vessel immune-complex vasculitis caused by type II/III cryoglobulins (polyclonal IgG bound to an IgM rheumatoid factor). Most commonly HCV-associated (80-90%); also HBV, HIV, autoimmune disease (SLE, Sjogren), lymphoproliferative disorders, and rarely idiopathic. Usually chronic/smouldering - Meltzer triad of palpable purpura, weakness, and arthralgia - but can present as rapidly progressive, life-threatening disease (RPGN, GI/pulmonary/CNS vasculitis, digital ischaemia). ED role: recognise it, assess organ threat, start the work-up, and treat severe disease.
Red flags
- Rapidly progressive glomerulonephritis / AKI
- Diffuse alveolar haemorrhage or respiratory failure
- GI vasculitis (abdominal pain, GI bleeding)
- CNS vasculitis (stroke, acute cognitive change)
- Digital ischaemia threatening amputation or necrotic ulcers
- Progressive mononeuritis multiplex (foot/wrist drop)
- Symptomatic hyperviscosity; severe hypertension
Assessment
Differential diagnosis
- ANCA-associated vasculitis (GPA/MPA/EGPA)
- IgA vasculitis (Henoch-Schonlein purpura)
- Drug-induced/hypersensitivity and infection-related vasculitis (endocarditis, poststreptococcal)
- Connective-tissue disease vasculitis (SLE, RA, Sjogren)
- Cutaneous small-vessel vasculitis
- Infective mimics (EBV, rickettsial, Lyme, babesiosis, brucellosis, endocarditis)
- TTP / other thrombotic microangiopathy; sepsis with purpura
Investigations
- Serum cryoglobulins - blood drawn into PREWARMED (37 C) tubes WITHOUT anticoagulant and kept warm to the lab (false negatives if not); cryocrit >0.5-1% or cryoglobulin >2-5 mg/dL is significant (30-40% of type II undetectable at presentation)
- Rheumatoid factor (usually high) and complement (C4 markedly low - often the most prominent finding; C3/CH50 less so)
- CBC - note temperature-dependent spurious WBC/platelet elevation from cryoglobulin particles
- Creatinine and urinalysis with sediment (MPGN - haematuria/proteinuria); LFTs
- HCV, HBV, and HIV serologies in all patients
- ANA, anti-dsDNA/ENA, and ANCA (to distinguish ANCA-associated vasculitis)
- SPEP/immunofixation and serum free light chains (type I / lymphoproliferative disease)
- Tissue biopsy (skin/kidney) in uncertainty - leukocytoclastic vasculitis / MPGN with intraluminal immune thrombi
Management
- Assess severity/organ threat: skin ulcer or necrosis, RPGN, GI vasculitis, diffuse alveolar haemorrhage/respiratory failure, CNS vasculitis, progressive neuropathy, digital ischaemia
- Mild disease: symptomatic care (NSAIDs, pain and wound care, avoid cold) plus treat the underlying cause
- Moderate-to-severe disease: immunosuppression (high-dose glucocorticoids + rituximab) and treat the underlying disease
- Timing of antivirals: for HCV, immunosuppression is usually started first; for HIV and HBV, start antiviral before or at the same time as immunosuppression
- Plasma exchange for the few critical scenarios (below)
- Pneumocystis prophylaxis for patients on high-dose steroids/immunosuppression; admit severe disease
Drugs & doses
Disposition
Complications & pitfalls
- MPGN / chronic kidney disease
- Progressive peripheral neuropathy
- Skin ulceration, necrosis, gangrene
- GI, pulmonary, or CNS vasculitis; hyperviscosity
- Markedly increased risk of B-cell non-Hodgkin lymphoma (especially HCV-associated)
- Rituximab-associated flare / acute serum sickness
Exam pearls
- Clue cluster: palpable purpura + low C4 + high RF, worsened by cold
- Cryocrit does NOT correlate with severity or treatment response - treat by organ involvement, not cryocrit
- Draw cryoglobulins in prewarmed anticoagulant-free tubes kept warm (false negatives common; 30-40% of type II undetectable at presentation)
- Spurious CBC WBC/platelet elevation if the sample cools
- Test HCV/HBV/HIV in everyone; for HIV and HBV start antiviral before or with immunosuppression
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.